Clover Health Investments Corp

Clover Health Investments Corp(CLOV)股票分析

$4.230

0.000 (0.00%)收盘时

Loading chart…
High
4.290
Open
4.180
VWAP
4.23
Vol
4.18M
Mkt Cap
645.37M
Low
4.170
Amount
17.68M
EV/EBITDA, TTM
15.03

Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is a technology platform that empowers providers to deliver intuitive data-driven, personalized care to help physicians detect, identify, and manage diseases earlier. This physician-enablement platform is designed to synthesize comprehensive, longitudinal sets of data to generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the relevant, personalized information about each patient to his or her provider. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states.

AI analysis of Clover Health Investments Corp (CLOV)

buy

Clover Health Investments Corp (CLOV) appears to be a good buy right now due to its recent strong financial performance, including a 55.5% year-over-year revenue increase to $743.2 million in Q2 2026, and a net income of $28 million, marking a significant turnaround from previous losses. Additionally, the stock has a current price of $4.23, which is below the analyst price target of $5.50, indicating potential upside. However, the forward P/E ratio is high at 81.97, which could pose a risk if growth expectations are not met.

估值指标

The current forward P/E ratio for Clover Health Investments Corp (CLOV) is 81.97, compared to its 5-year average forward P/E of 1.85.

Forward P/E

Strongly Overvalued
5Y Average P/E
1.85
Current P/E
81.97
高估
38.02
低估
-34.32

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
10.34
Current EV/EBITDA
15.03
高估
29.66
低估
-8.97

Forward P/S

Fair
5Y Average P/S
0.57
Current P/S
0.63
高估
0.93
低估
0.21

Alphio AI Price Scenarios for CLOV

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CLOV

$3.66

情景价格

B

Base

Base · 50%CLOV

$3.60

情景价格

B

Bear

Bear · 25%CLOV

$3.51

情景价格

Whales holding CLOV

G

GMT Capital Corp.

+ HoldingCLOV

-2.06%

3M Return

事件时间线

2026-08-05 (ET)

18:00:00

FY26 Medicare Advantage Memberships Expected at 156,000-158,000

18:00:00

Q2 Revenue of $743.2M, Exceeds Expectations

2026-06-10 (ET)

16:30:00

US Stocks Drop Sharply Amid Renewed US-Iran Tensions

12:10:00

Major U.S. Averages Decline Amid Escalating Geopolitical Tensions

12:10:00

Clover Health Stock Price Rises

资讯

CLOV FAQ — answered by Alphio AI

Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is a technology platform that empowers providers to deliver intuitive data-driven, personalized care to help physicians detect, identify, and manage diseases earlier. This physician-enablement platform is designed to synthesize comprehensive, longitudinal sets of data to generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the relevant, personalized information about each patient to his or her provider. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states. It operates in the Healthcare sector (HOSPITAL & MEDICAL SERVICE PLANS industry).

Clover Health Investments Corp (CLOV) appears to be a good buy right now due to its recent strong financial performance, including a 55.5% year-over-year revenue increase to $743.2 million in Q2 2026, and a net income of $28 million, marking a significant turnaround from previous losses. Additionally, the stock has a current price of $4.23, which is below the analyst price target of $5.50, indicating potential upside. However, the forward P/E ratio is high at 81.97, which could pose a risk if growth expectations are not met.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始